BrightPath Biotherapeutics Co., Ltd., First Half Net Income Loss Narrows, July-September Net Income Loss Narrows
4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】
Earnings ReportBrightPath Biotherapeutics Co., Ltd. <4594> [TSE-G] announced its financial results after the market closed on November 8th (15:30). The net loss (non-consolidated) for the cumulative second quarter of the fiscal year ending March 2025 (April to September) was a reduced loss of 538 million yen (compared to a loss of 553 million yen in the same period last year).
Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the net loss for the October to March period (second half) is expected to further decrease to loss of 389 million yen (compared to a loss of 615 million yen in the same period last year).
In the most recent three-month period, from July to September (2Q), the net loss improved to a deficit of loss of 208 million yen (compared to a loss of 258 million yen in the same period last year).
Kabutan News
Actual Performance and Financial Trends
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Progress Rate vs. First Half |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
|
|
0M | -805M | -809M | -810M | -14.2 | ー | Nov 11, 2022 | J-GAAP |
|
|
0M | -550M | -551M | -553M | -8.8 | ー | Nov 10, 2023 | J-GAAP |
|
|
0M | -542M | -537M | -538M | -7.1 | ー | Nov 8, 2024 | J-GAAP |
| YoY | － | +1.5% | +2.5% | +2.7% | +19.3% |
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Adj. Dividend |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2024 Guidance | ー | ー | ー | ー | － | 0 | May 10, 2024 | J-GAAP |
| Apr - Sep, 2024 Results | 0M | -542M | -537M | -538M | -7.1 | 0 | Nov 8, 2024 | J-GAAP |
| Revision Rate | － | － | － | － | － |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Adj. Dividend |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
|
|
0M | -605M | -607M | -615M | -9.6 | 0 | May 10, 2024 | J-GAAP |
|
Guidance
Oct - Mar, 2024
|
0M | -383M | -388M | -389M | -4.4 | 0 | Nov 8, 2024 | J-GAAP |
| YoY | － | +36.7% | +36.1% | +36.7% | +54.6% |
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Adj. Dividend |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
|
|
5M | -1,467M | -1,473M | -1,485M | -24.9 | 0 | May 12, 2023 | J-GAAP |
|
|
0M | -1,155M | -1,158M | -1,168M | -18.2 | 0 | May 10, 2024 | J-GAAP |
|
Guidance
Mar, 2025
|
0M | -925M | -925M | -927M | -10.4 | 0 | May 10, 2024 | J-GAAP |
| YoY | － | +19.9% | +20.1% | +20.6% | +43.1% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Operating Profit Margin |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
|
|
0M | -257M | -258M | -258M | -4.1 | -Inf | Nov 10, 2023 | J-GAAP |
|
|
0M | -397M | -396M | -400M | -6.4 | -Inf | Feb 9, 2024 | J-GAAP |
|
|
0M | -208M | -211M | -215M | -3.4 | -Inf | May 10, 2024 | J-GAAP |
|
|
0M | -326M | -329M | -330M | -4.7 | -Inf | Aug 9, 2024 | J-GAAP |
|
|
0M | -216M | -208M | -208M | -2.8 | -Inf | Nov 8, 2024 | J-GAAP |
| YoY | － | +16.0% | +19.4% | +19.4% | +33.1% |